NeuroVive Pharmaceutical AB recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 in order to strengthen the company's communication resources. Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has worked for 15 years, the last eight as Assistant Director Investor Relations & Business Development.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1978 SEK | -2.08% | +4.11% | -19.43% |
Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.43% | 23.52M | |
+8.68% | 114B | |
+10.77% | 104B | |
-12.99% | 22.41B | |
-1.19% | 22.28B | |
-5.38% | 19.07B | |
-38.29% | 18B | |
-4.87% | 17.89B | |
+7.47% | 14.28B | |
+35.78% | 12.55B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- NeuroVive Pharmaceutical AB Appoints Cecilia Hofvander as Investor Relations and Communications Director, Effective June 1, 2016